

primary studies - published RCT

Efficacy and Safety of a New Formulation of Pancrelipase (Ultrase MT20) in the Treatment of Malabsorption in Exocrine Pancreatic Insufficiency in Cystic Fibrosis.

Code: PM21197074

Year: 2010 **Date:** 2010

Author: Konstan MW

Study design (if review, criteria of inclusion for studies)

RCT

Participants

CF Patients (n = 31). Exocrine Pancreatic Insufficiency

Interventions

Patients were randomized in a crossover design comparing this pancrelipase with placebo during 2 inpatient evaluation periods (6-7 days each).

Outcome measures

Fat and protein/nitrogen ingestion and excretion were measured from food diaries and 72-hour stool collections. CFA% and CNA% were calculated for each period and compared.

Main results

Twenty-four patients provided analyzable data. This pancrelipase increased mean CFA% and CNA% (+34.7% and +25.7%, resp., P

Authors' conclusions

This pancrelipase is a safe and effective treatment for malabsorption associated with exocrine PI in patients with CF.

<http://dx.doi.org/10.1155/2010/898193>

See also

Gastroenterol Res Pract. 2010;2010:898193. Epub 2010 Dec 8

Keywords

ULTRASE; Pancreatic Enzyme Replacement Therapy; pharmacological_intervention; Pancreas insufficiency; Pancreatic Diseases; Gastrointestinal Diseases; Gastrointestinal Agents; Pancrelipase;